Publications by authors named "Jeffrey Marbach"

Mitral regurgitation complicated by cardiogenic shock creates a unique and devastating risk profile for patients and poses significant difficulties for physicians who lack a comprehensive range of effective management strategies. Supportive measures such as intravenous vasodilators, intra-aortic balloon pumps, and percutaneous ventricular assist devices are often necessary to stabilize patients prior to definitive treatment with surgical mitral valve replacement or trans-catheter edge-to-edge repair. This review evaluates the evidence for the available supportive and definitive management strategies in patients with mitral regurgitation complicated by cardiogenic shock and presents a framework to aid clinicians in navigating the complex clinical decision-making process.

View Article and Find Full Text PDF
Article Synopsis
  • Focused cardiac ultrasound (FoCUS) is increasingly used in clinical practice, but there is limited research on its use with artificial intelligence (AI) for assessing left ventricular ejection fraction (LVEF).
  • A study with 449 participants compared AI-assisted LVEF assessments using FoCUS by novice and experienced users against traditional transthoracic echocardiograms (TTE), finding excellent agreement in outcomes and high accuracy for identifying abnormal heart function.
  • The results indicated that FoCUS AI-assisted assessments generated reliable LVEF estimates across user experience levels, making it a promising tool for diverse clinical settings.
View Article and Find Full Text PDF

Objectives: Inotropic support is commonly used in patients with cardiogenic shock (CS). High-quality data guiding the use of dobutamine or milrinone among this patient population is limited. We compared the efficacy and safety of these two inotropes among patients with low cardiac output states (LCOS) or CS.

View Article and Find Full Text PDF
Article Synopsis
  • Cardiogenic shock significantly contributes to deaths in patients experiencing acute myocardial infarction, with the study focusing on differences between those with ST-segment elevation myocardial infarction (STEMI-CS) and those with non-ST-segment elevation myocardial infarction (NSTEMI-CS).
  • Among 1,110 patients analyzed, in-hospital mortality rates were high and similar for both groups, though those with out-of-hospital cardiac arrest had notably worse outcomes, especially in the NSTEMI-CS group.
  • Despite the increase in the use of drugs and mechanical circulatory support during their hospital stay, the risk of in-hospital mortality remained elevated for both STEMI-CS and NSTEMI-CS patients, indicating a need for further research through
View Article and Find Full Text PDF

Background: Cardiogenic shock (CS) is a state of end-organ hypoperfusion related to cardiac dysfunction. Current guidelines recommend consideration of inotrope therapy in patients with CS, however no robust data support their use. The purpose of the CAPITAL DOREMI2 trial is to examine the efficacy and safety of inotrope therapy against placebo in the initial resuscitation of patients with CS.

View Article and Find Full Text PDF
Article Synopsis
  • Inotropic support is commonly used for patients with cardiogenic shock (CS), but existing data on arrhythmic events in these patients is potentially biased.
  • The DOREMI trial compared the effects of dobutamine and milrinone on patients, assessing the incidence and impact of arrhythmias on in-hospital outcomes.
  • Nearly half of the patients experienced arrhythmic events, with ventricular arrhythmias linked to higher mortality, while several patient characteristics could help identify those at greater risk for such complications.
View Article and Find Full Text PDF

Purpose Of Review: Early revascularization, invasive hemodynamic profiling, and initiation of temporary mechanical circulatory support (MCS) have all become routine components of cardiogenic shock (CS) management. Despite this evolution in clinical practice, patient selection and timing of treatment initiation remain a significant barrier to achieving sustained improvement in CS outcomes. Recent efforts to standardize CS management, through the development of treatment algorithms, have relied heavily on surrogate endpoints to drive therapeutic decisions.

View Article and Find Full Text PDF

Purpose Of Review: The goal of this review is to summarize the current knowledge on the role of medical management of cardiogenic shock in the era of mechanical circulatory support based on important lessons from clinical trials and routine clinical practice, with a focus on providing practical recommendations that can improve contemporary in-hospital management.

Recent Findings: Despite an increasing number of invasive therapies being used to manage cardiogenic shock, evidence-based treatment regimens known to improve outcomes are limited. Medical management of cardiogenic shock includes pharmacological interventions aimed at optimizing determinants of cardiac output-contractility, preload, afterload, and heart rate.

View Article and Find Full Text PDF

Venoarterial extracorporeal membrane oxygenation (VA-ECMO) provides cardiovascular and respiratory support for patients in cardiogenic shock; yet, complications are a frequent source of morbidity and mortality. Limb ischemia can be potentially mitigated by limp perfusion protection strategies (LPPS). We performed a systematic review and meta-analysis to evaluate the safety and efficacy of two LPPS in patients treated with peripheral VA-ECMO - prophylactic insertion of a distal perfusion catheter (DPC) and small bore (<17 Fr) arterial return cannula.

View Article and Find Full Text PDF
Article Synopsis
  • Recent studies highlight the benefit of early mechanical circulatory support in cardiogenic shock but lack clear real-time therapeutic targets based on clinical data.
  • A post hoc analysis of the DOREMI trial found that lactate clearance can effectively predict in-hospital survival, with complete lactate clearance showing strong association with patient outcomes.
  • These findings support using lactate clearance as a viable treatment target for improving mortality rates in future cardiogenic shock treatments.
View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to improve post-revascularization care for patients and document ongoing risk factors a year after treatment, using a web-based registry.
  • Conducted at the University of Ottawa Heart Institute, data from 4147 patients who underwent various revascularization procedures were analyzed to track complications like major adverse cardiovascular events (MACE) over a median follow-up of 13.3 months.
  • Results showed that 11% of patients had MACE within the follow-up period, with specific attention given to women and patients with multiple risk factors, highlighting the need for better management of ongoing health risks post-procedure.
View Article and Find Full Text PDF

Background: Left ventricular unloading with Impella may improve survival outcomes in patients with acute myocardial infarction complicated by cardiogenic shock (AMI-CS). However, the optimal timing to initiate left ventricular unloading has yet to be established. Therefore, we conducted a systematic review and meta-analysis to compare survival in patients with AMI-CS who were supported with Impella prior to PCI (pre-PCI) to those in whom support was initiated following PCI (post-PCI).

View Article and Find Full Text PDF

Background The randomized DOREMI (Dobutamine Compared to Milrinone) clinical trial evaluated the efficacy and safety of milrinone and dobutamine in patients with cardiogenic shock. Whether the results remain consistent when stratified by acute myocardial infarction remains unknown. In this substudy, we sought to evaluate differences in clinical management and outcomes of acute myocardial infarction complicated by cardiogenic shock (AMICS) versus non-AMICS.

View Article and Find Full Text PDF

Objective: Elevated blood lactate levels are strongly associated with mortality in patients with cardiogenic shock. Recent evidence suggests that the degree and rate at which blood lactate levels decrease after the initiation of treatment may be equally important in patient prognosis. We performed a systematic review and meta-analysis to evaluate the usefulness of lactate clearance as a prognostic factor in cardiogenic shock.

View Article and Find Full Text PDF

Aims: Cardiogenic shock (CS) is a state of low cardiac output resulting in end-organ hypoperfusion. Despite high in-hospital mortality rates, little evidence exists regarding the optimal mean arterial pressure (MAP) target in CS. We therefore evaluated the relationship between achieved MAP and clinical outcomes in patients with CS.

View Article and Find Full Text PDF

Background: Cardiogenic shock (CS) is associated with significant morbidity and mortality. The impact of beta-blocker (BB) use on patients who develop CS remains unknown. We sought to evaluate the clinical outcomes and hemodynamic response profiles in patients treated with BB in the 24 h prior to the development of CS.

View Article and Find Full Text PDF

Background: Cardiogenic shock is associated with substantial morbidity and mortality. Although inotropic support is a mainstay of medical therapy for cardiogenic shock, little evidence exists to guide the selection of inotropic agents in clinical practice.

Methods: We randomly assigned patients with cardiogenic shock to receive milrinone or dobutamine in a double-blind fashion.

View Article and Find Full Text PDF

Purpose Of Review: Over the past several years, the role of short-term mechanical circulatory support (MCS) devices has become the dominant focus in efforts to improve outcomes in patients with cardiogenic shock (CS). Alongside these efforts, temporary MCS devices have been increasingly used to support patients prior to cardiac surgery, during high-risk percutaneous coronary intervention, awaiting cardiac transplantation, and in the setting of refractory cardiac arrest. The present review aims to provide an update on the recent literature evaluating the evolving role of temporary MCS devices, and to provide insights into the current challenges and future directions of MCS research.

View Article and Find Full Text PDF

Atherosclerosis remains a leading cause of morbidity and mortality, with revascularization remaining a cornerstone of management. Conventional revascularization modalities remain challenged by target vessel reocclusion-an event driven by mechanical, thrombotic, and proliferative processes. Despite considerable advancements, restenosis remains the focus of ongoing research.

View Article and Find Full Text PDF
Article Synopsis
  • Acute kidney injury (AKI) is a significant concern for patients undergoing primary percutaneous coronary intervention (PCI) due to its impact on long-term outcomes in those suffering from STEMI.
  • This study analyzed data from the SAFARI-STEMI trial, comparing the incidence of AKI in patients who underwent PCI via radial artery (RA) versus femoral artery (FA) access.
  • The results showed no significant difference in AKI rates between the two access methods, suggesting that the choice of access site may not influence AKI occurrence in STEMI patients as previously thought.
View Article and Find Full Text PDF